Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials-Reference-Cited by-同舟云学术

Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials

Published:2021-08-26 Issue:1 Volume:44 Page:127-134
ISSN:1751-5521
Container-title:International Journal of Laboratory Hematology
language:en
Short-container-title:Int J Lab Hematology

Author:

Chen Yan‐Ting¹,Valent Erik T.¹^ORCID,Beers Erik H.¹,Kuiper Rowan¹,Oliva Stefania²,Haferlach Torsten³,Chng Wee‐Joo⁴⁵⁶,Vliet Martin H.¹,Sonneveld Pieter⁷,Larocca Alessandra²

Affiliation:

1. SkylineDx Rotterdam The Netherlands

2. Myeloma Unit Division of Hematology University of Turin Turin Italy

3. MLL Munich Leukemia Laboratory Munich Germany

4. National University Cancer Institute National University Health System Singapore City Singapore

5. Department of Medicine Yong Loo Lin School of Medicine National University of Singapore Singapore City Singapore

6. Cancer Science Institute of Singapore National University of Singapore Singapore City Singapore

7. Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands

Publisher

Wiley

Subject

Biochemistry (medical),Clinical Biochemistry,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.13691

Reference36 articles.

1. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

2. Improved survival in multiple myeloma and the impact of novel therapies

3. Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

4. Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease Characteristics

5. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy;American Journal of Hematology;2024-04-13

2. Individualized dynamic risk assessment for multiple myeloma;2024-04-03

3. Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients;International Journal of Molecular Sciences;2022-10-18

4. Hämatologische Labordiagnostik 2022;Trillium Diagnostik;2022-09-22

5. Chromosome Territories in Hematological Malignancies;Cells;2022-04-17